UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Tesla Inc (TSLA)

Tesla Inc (TSLA)
266.13 x 2 266.44 x 5
Pre-market by (Cboe BZX)
272.06 -16.08 (-5.58%) 03/26/25 [NASDAQ]
266.13 x 2 266.44 x 5
Pre-market 266.35 -5.71 (-2.10%) 04:15 ET
Quote Overview for Wed, Mar 26th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
271.28
Day High
288.20
Open 283.60
Previous Close 288.14 288.14
Volume 156,254,406 156,254,406
Avg Vol 125,931,055 125,931,055
Stochastic %K 91.80% 91.80%
Weighted Alpha +18.19 +18.19
5-Day Change +36.20 (+15.35%) +36.20 (+15.35%)
52-Week Range 138.80 - 488.54 138.80 - 488.54
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 926,807,296
  • Shares Outstanding, K 3,216,517
  • Annual Sales, $ 97,690 M
  • Annual Income, $ 7,130 M
  • EBIT $ 7,076 M
  • EBITDA $ 12,444 M
  • 60-Month Beta 2.50
  • Price/Sales 9.17
  • Price/Cash Flow 71.87
  • Price/Book 12.16

Options Overview Details

View History
  • Implied Volatility 72.06% ( +1.58%)
  • Historical Volatility 86.47%
  • IV Percentile 96%
  • IV Rank 63.47%
  • IV High 89.94% on 03/10/25
  • IV Low 40.99% on 05/10/24
  • Put/Call Vol Ratio 0.88
  • Today's Volume 2,908,691
  • Volume Avg (30-Day) 2,909,003
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 8,706,279
  • Open Int (30-Day) 8,439,756

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 40 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.51
  • Number of Estimates 7
  • High Estimate 0.66
  • Low Estimate 0.32
  • Prior Year 0.35
  • Growth Rate Est. (year over year) +45.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
217.02 +25.36%
on 03/11/25
Period Open: 290.80
303.94 -10.49%
on 03/03/25
-18.74 (-6.44%)
since 02/26/25
3-Month
217.02 +25.36%
on 03/11/25
Period Open: 454.13
450.00 -39.54%
on 12/27/24
-182.07 (-40.09%)
since 12/26/24
52-Week
138.80 +96.01%
on 04/22/24
Period Open: 177.67
488.54 -44.31%
on 12/18/24
+94.39 (+53.13%)
since 03/26/24

Most Recent Stories

More News
Billionaire Bill Ackman Is Buying a Brilliant Robotaxi Stock Up 145% in 2 Years (Hint: Not Tesla)

Billionaire Bill Ackman is the CEO of Pershing Square Capital Management, a hedge fund that returned 210% in the past five years. Comparatively, the S&P 500 (SNPINDEX: ^GSPC) advanced 101% during the same...

GOOGL : 165.06 (-3.22%)
GOOG : 167.14 (-3.27%)
TSLA : 272.06 (-5.58%)
$SPX : 5,712.20 (-1.12%)
UBER : 74.18 (-1.89%)
Stock market today: Asian shares sag after Trump raises tariffs on auto imports

Shares have sagged in Asia after President Donald Trump announced he will raise tariffs on imported cars

NVDA : 113.76 (-5.74%)
TSLA : 272.06 (-5.58%)
GM : 50.95 (-3.12%)
SMCI : 37.04 (-8.86%)
$SPX : 5,712.20 (-1.12%)
$DOWI : 42,454.79 (-0.31%)
$IUXX : 19,916.99 (-1.83%)
Quiver Stock Research: Trump’s Auto Tariffs Threaten to Upend Market Recovery

Wall Street ended sharply lower on Wednesday, weighed down by tech and auto stocks as uncertainty over impending U.S. tariffs unsettled investors. A report suggesting President Donald Trump may announce...

NVDA : 113.76 (-5.74%)
LMT : 445.17 (+0.70%)
TSLA : 272.06 (-5.58%)
AVGO : 179.27 (-4.78%)
GM : 50.95 (-3.12%)
F : 10.30 (+0.10%)
SPY : 568.59 (-1.19%)
GME : 28.36 (+11.65%)
BA : 178.55 (-2.21%)
X Ad Comeback: Musk’s (TSLA) Strategy Pays Off

X is poised to post its first annual ad revenue increase since Elon Musk’s (TSLA) $44 billion acquisition in 2022, according to new estimates from Emarketer. Analysts attribute this rebound to Musk’s...

TSLA : 272.06 (-5.58%)
Boeing-Lockheed’s (BA) Vulcan Rockets Past SpaceX in Defense Launch Race

Boeing (BA) and Lockheed Martin’s (LMT) Vulcan rocket secured a key certification to launch U.S. national security satellites, marking a pivotal shift in the defense-focused space race. The approval...

LMT : 445.17 (+0.70%)
TSLA : 272.06 (-5.58%)
BA : 178.55 (-2.21%)
US robotics companies push for national strategy, including a central office, to compete with China

American robotics companies are pushing for a national robotics strategy, including a central government robotics office, to promote the industry at a time that Beijing is making intelligent robots a top...

GOOGL : 165.06 (-3.22%)
NVDA : 113.76 (-5.74%)
TSLA : 272.06 (-5.58%)
GM : 50.95 (-3.12%)
Breaking Down the Mag 7 Earnings Outlook

Note: The following is an excerpt from this week’s Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please...

MSFT : 389.97 (-1.31%)
NVDA : 113.76 (-5.74%)
GOOGL : 165.06 (-3.22%)
META : 610.98 (-2.45%)
AAPL : 221.53 (-0.99%)
TSLA : 272.06 (-5.58%)
AMZN : 201.13 (-2.23%)
Breaking Down the Mag 7 Earnings Outlook

Note: The following is an excerpt from this week’s Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please...

MSFT : 389.97 (-1.31%)
NVDA : 113.76 (-5.74%)
GOOGL : 165.06 (-3.22%)
META : 610.98 (-2.45%)
AAPL : 221.53 (-0.99%)
TSLA : 272.06 (-5.58%)
AMZN : 201.13 (-2.23%)
This Dividend Stock Yields 5.9%. Should You Buy It Now?

Ford stock offers investors a balance of growth and income.

TSLA : 272.06 (-5.58%)
F : 10.30 (+0.10%)
$SPX : 5,712.20 (-1.12%)
GM : 50.95 (-3.12%)
RIVN : 12.10 (-2.10%)
Hyundai shows off its new $7.6B electric vehicle plant in Georgia as Trump announces tariffs

Hyundai says it will expand production capacity by two-thirds at its sprawling new electric vehicle plant in Georgia

TSLA : 272.06 (-5.58%)
Neurocrine: Q2 Earnings Snapshot

Neurocrine: Q2 Earnings Snapshot

NBIX : 114.45 (-1.49%)
Neurocrine: Q1 Earnings Snapshot

Neurocrine: Q1 Earnings Snapshot

NBIX : 114.45 (-1.49%)
Neurocrine: Q4 Earnings Snapshot

Neurocrine: Q4 Earnings Snapshot

NBIX : 114.45 (-1.49%)
Neurocrine: Q3 Earnings Snapshot

Neurocrine: Q3 Earnings Snapshot

NBIX : 114.45 (-1.49%)
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2023 financial results conference call and...

NBIX : 114.45 (-1.49%)
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints

CAHtalyst™ Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children and...

NBIX : 114.45 (-1.49%)
Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the...

NBIX : 114.45 (-1.49%)
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application...

NBIX : 114.45 (-1.49%)
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data from the Phase 3 CAHtalyst™ Adult Study evaluating the...

NBIX : 114.45 (-1.49%)
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the...

NBIX : 114.45 (-1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Tesla is the market leader in battery-powered electric car sales in the United States, with roughly 70% market share. The company's flagship Model 3 is the best-selling EV model in the United States. Tesla, which has managed to garner the reputation of a gold standard over the years, is now a far bigger...

See More

Key Turning Points

3rd Resistance Point 300.86
2nd Resistance Point 292.88
1st Resistance Point 282.47
Last Price 272.06
1st Support Level 264.08
2nd Support Level 256.10
3rd Support Level 245.69

See More

52-Week High 488.54
Fibonacci 61.8% 354.94
Fibonacci 50% 313.67
Fibonacci 38.2% 272.40
Last Price 272.06
52-Week Low 138.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.